187 related articles for article (PubMed ID: 31399529)
1. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
Sharpley FA; Fontana M; Martinez-Naharro A; Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Hawkins PN; Wechalekar AD
Haematologica; 2020 May; 105(5):1405-1413. PubMed ID: 31399529
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic score of cardiac involvement in AL amyloidosis.
Nicol M; Baudet M; Brun S; Harel S; Royer B; Vignon M; Lairez O; Lavergne D; Jaccard A; Attias D; Macron L; Gayat E; Cohen-Solal A; Arnulf B; Logeart D
Eur Heart J Cardiovasc Imaging; 2020 May; 21(5):542-548. PubMed ID: 31292624
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
4. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T
ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Nicol M; Deney A; Lairez O; Vergaro G; Emdin M; Carecci A; Inamo J; Montfort A; Neviere R; Damy T; Harel S; Royer B; Baudet M; Cohen-Solal A; Arnulf B; Logeart D
Eur J Heart Fail; 2021 Feb; 23(2):231-239. PubMed ID: 33006180
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Left Ventricular
Clerc OF; Datar Y; Cuddy SA; Bianchi G; Taylor A; Benz DC; Robertson M; Kijewski MF; Jerosch-Herold M; Kwong RY; Ruberg FL; Liao R; Di Carli MF; Falk RH; Dorbala S
medRxiv; 2023 Sep; ():. PubMed ID: 37745589
[TBL] [Abstract][Full Text] [Related]
7. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
9. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
10. Independent Prognostic Utility of
Choi YJ; Koh Y; Lee HJ; Hwang IC; Park JB; Yoon YE; Kim HL; Kim HK; Kim YJ; Cho GY; Sohn DW; Paeng JC; Lee SP
J Nucl Med; 2022 Jul; 63(7):1064-1069. PubMed ID: 34916248
[No Abstract] [Full Text] [Related]
11. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.
Klaassen SHC; Tromp J; Nienhuis HLA; van der Meer P; van den Berg MP; Blokzijl H; van Veldhuisen DJ; Hazenberg BPC
Am J Cardiol; 2018 Jan; 121(1):107-112. PubMed ID: 29153245
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of novel biomarkers in patients with AL amyloidosis.
Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES
Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944
[TBL] [Abstract][Full Text] [Related]
13. Serum high-density lipoprotein cholesterol serves as a prognostic marker for light-chain cardiac amyloidosis.
Yang T; Wan K; Song R; Guo X; Xu Y; Wang J; Zhang Q; Alexander KM; Liao R; Chen Y
Int J Cardiol; 2021 Feb; 325():96-102. PubMed ID: 33080283
[TBL] [Abstract][Full Text] [Related]
14. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
[TBL] [Abstract][Full Text] [Related]
15. Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.
Wan K; Sun J; Han Y; Liu H; Yang D; Li W; Wang J; Cheng W; Zhang Q; Zeng Z; Chen Y
Circ J; 2018 Feb; 82(3):739-746. PubMed ID: 29093431
[TBL] [Abstract][Full Text] [Related]
16. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
[TBL] [Abstract][Full Text] [Related]
17. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
[TBL] [Abstract][Full Text] [Related]
18. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
19. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
Dispenzieri A; Gertz MA; Kumar SK; Lacy MQ; Kyle RA; Saenger AK; Grogan M; Zeldenrust SR; Hayman SR; Buadi F; Greipp PR; Leung N; Russell SR; Dingli D; Lust JA; Rajkumar SV; Jaffe AS
Heart; 2014 Mar; 100(5):383-8. PubMed ID: 24402772
[TBL] [Abstract][Full Text] [Related]
20. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]